Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 107Colonic Neoplasms 91Pancreatic Neoplasms 88Stomach Neoplasms 75Neoplasm Metastasis 61Esophageal Neoplasms 40Carcinoma, Hepatocellular 31Lymphoma 24Adenocarcinoma Of Esophagus 24Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Adenocarcinoma 19Leukemia 17Cholangiocarcinoma 15Biliary Tract Neoplasms 15Burkitt Lymphoma 14Gastrointestinal Neoplasms 12Lymphoma, Non-Hodgkin 11Osteosarcoma 9Liver Neoplasms 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Peritoneal Neoplasms 8Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Lymphoma, Large B-Cell, Diffuse 7Bile Duct Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Multiple Myeloma 6

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Cancer × Leucovorin × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡